SC 13G/A - Erasca, Inc. (0001761918) (Subject)

SC 13G/A - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G/A - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G/A - Erasca, Inc. (0001761918) (Subject)

SC 13D/A - Erasca, Inc. (0001761918) (Subject)

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to dateFavorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanomaRandomized Stage 1 readout for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating

Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from $7 to $4.

U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday. Shares of e.l.f. Beauty, Inc. (NYSE:ELF) rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter earnings. e.l.f. Beauty reported adjusted earnings of 53 cents per share, beating the 32-cent estimate, according to data from Benzinga Pro. Quarterly sales clocked in at $321.14 million, beating the $292.17 million analyst consensus estimate, primarily driven by strength across retailer and e-commerce channels. e.l.f. Beauty said it sees fiscal year earnings between $3.20 and $3.25 per share, versus the $3.51 per share estimate, and full-year revenue in a

The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Marygold Companies The Trade: The Marygold Companies, Inc. (NYSE:MGLD) 10% owner Nicholas & Melinda Gerber Living Trust bought a total of 80,000 shares at an average price of $1.35. To acquire these shares, it cost around $107,760. What's Happ

HC Wainwright & Co. analyst Andres Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from $8 to $5.

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 10 points on Friday. Shares of DXC Technology Company (NYSE:DXC) fell sharply in today's pre-market trading after the company issued weak guidance. DXC Technology reported quarterly earnings of 97 cents per share which beat the analyst consensus estimate of 83 cents. Quarterly sales came in at $3.386 billion which beat the analyst consensus estimate of $3.366 billion, according to data from Benzinga Pro. DXC Technology said it sees fiscal year 2025 adjusted earnings of between $2.50 and $3.00 per share, versus the $3.49 estimate, and full-year revenue in a range of $12.67 billion to $12.95 billi

Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering

The Company will deprioritize the ERAS-007 program as the Company believes the clinical efficacy data from the HERKULES-3 clinical trial evaluating ERAS-007 in combination with encorafenib and cetuximab (“EC”) in patients with EC-naïve BRAFm colorectal cancer do not support continued evaluation. The Company will also deprioritize its ERAS-801 program and explore further advancement of the program via select investigator-sponsored trials. Finally, the Company will discontinue its existing internal ERAS-4 pan-KRAS program, although certain of the existing ERAS-4 molecules may serve as potential backup compounds for ERAS-4001.

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca's addressable population Erasca to host conference call and webcast today at 8:30 am ET SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into an exclusive worldwide license agreement with Novartis (NYSE:NVS) for naporafenib, a Phase

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK path

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)Location: InterContinental Hotel, Boston, MAFormat: Fireside Chat Date and Time: Tuesday, November 12, 2:00 pm Eastern Time Jefferies London Healthcare Conference (November 19 – 21, 2024)Location: The Waldorf Hilton, London, U

Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial SEACRAFT-2 has potential for approval based on alignment with US and European regulatory agencies on path for tissue-specific indication in melanoma; Stage 1 randomized data expected in 2025 Rapid progress across RAS targeting franchise; planned IND submissions remain on track Erasca to host investor event today at 8:30 AM Eastern Time SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerc

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable survival was previously demonstrated in pooled analyses Erasca to host virtual R&D update for investors on Thursday, October 24, 2024, at 8:30 AM ET SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in September 2024 and will also participate in one-on-one investor meetings. 22nd Annual Morgan Stanley Global Healthcare ConferenceLocation: New York Marriott Marquis, New York, NYFormat: Fireside ChatDate and Time: Thursday, September 5, 12:20 – 12:55 pm Eastern Time 2024 Cantor Global Healthcare ConferenceLocation: InterContinental Barclay, New York, NYFormat

In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated SEACRAFT-2 registrational trial in patients with NRASm melanoma; randomized data for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $460 million as of June 30, 2024 is expected to fund operations into H1 2027 SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercia

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomized Stage 1 readout for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025 SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the initiation of the global SEACRAFT-2 Phase 3 trial eva

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings. Jefferies Global Healthcare Conference (June 5 – 6, 2024) Location: Marriott Marquis, New York, NY Format: Presentation Date and Time: Thursday, June 6, 10:30 – 10:55 am E

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional shares. All of the shares in the offering were sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other estimated offering expe

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

Jefferies initiated coverage of Erasca with a rating of Buy and set a new price target of $6.00

CapitalOne initiated coverage of Erasca with a rating of Overweight and set a new price target of $8.00

BofA Securities downgraded Erasca from Buy to Neutral and set a new price target of $6.00 from $11.00 previously

H.C. Wainwright initiated coverage of Erasca with a rating of Buy and set a new price target of $10.00

Mizuho initiated coverage of Erasca with a rating of Buy and set a new price target of $9.00

Goldman initiated coverage of Erasca with a rating of Buy and set a new price target of $10.00

Morgan Stanley upgraded Erasca from Equal-Weight to Overweight and set a new price target of $15.00

Evercore ISI Group initiated coverage of Erasca with a rating of Outperform and set a new price target of $45.00

Guggenheim initiated coverage of Erasca with a rating of Buy and set a new price target of $25.00

Morgan Stanley initiated coverage of Erasca with a rating of Equal-Weight and set a new price target of $25.00

10-Q - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

10-Q - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

424B5 - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

EFFECT - Erasca, Inc. (0001761918) (Filer)